Literature DB >> 22093617

Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells.

Norihisa Uehara1, Sayaka Kanematsu, Hisanori Miki, Katsuhiko Yoshizawa, Airo Tsubura.   

Abstract

Vorinostat is a histone deacetylase inhibitor that effectively suppresses cancer-cell proliferation by inducing cell-cycle arrest and/or apoptosis. We now show the involvement of p38 mitogen-activated protein kinase (MAPK) in the regulation of vorinostat-induced apoptosis in MDA-MB-231 human breast cancer cells. Vorinostat induced the hyperacetylation of histone H3, which correlated to apoptosis induction. Vorinostat-induced apoptosis occurred in parallel with the phosphorylation of p38 MAPK and the dephosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2). Knockdown of p38 MAPK prominently abrogated apoptosis induction and was accompanied by decreased caspase-3 cleavage. These findings support the notion that the activation of the p38 MAPK pathway followed by caspase-3 cleavage is responsible for vorinostat-induced apoptosis in MDA-MB-231 cells.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22093617     DOI: 10.1016/j.canlet.2011.07.032

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

1.  Comparative effects of 4-phenyl-3-butenoic acid and vorinostat on cell growth and signaling.

Authors:  Timothy J Burns; Amna Ali; Diane F Matesic
Journal:  Anticancer Res       Date:  2015-02       Impact factor: 2.480

2.  Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.

Authors:  Deepali Kurundkar; Ritesh K Srivastava; Sandeep C Chaudhary; Mary E Ballestas; Levy Kopelovich; Craig A Elmets; Mohammad Athar
Journal:  Toxicol Appl Pharmacol       Date:  2012-11-09       Impact factor: 4.219

3.  Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity.

Authors:  Thomas W Hanigan; Shaimaa M Aboukhatwa; Taha Y Taha; Jonna Frasor; Pavel A Petukhov
Journal:  Cell Chem Biol       Date:  2017-09-21       Impact factor: 8.116

4.  Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.

Authors:  Ahmad Salahuddin; Heba Ghanem; Gamal A Omran; Maged Wasfy Helmy
Journal:  Med Oncol       Date:  2022-07-18       Impact factor: 3.738

5.  Proteomic study of benign and malignant pleural effusion.

Authors:  Hongqing Li; Zhonghao Tang; Huili Zhu; Haiyan Ge; Shilei Cui; Weiping Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-05       Impact factor: 4.553

6.  p38γ overexpression in gliomas and its role in proliferation and apoptosis.

Authors:  Kui Yang; Yunsheng Liu; Zhixiong Liu; Jinfang Liu; Xin Liu; Xin Chen; Chuntao Li; Yu Zeng
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

7.  BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective prediction using large scale microarray database.

Authors:  Chifeng Ma; Hung-I Chen; Mario Flores; Yufei Huang; Yidong Chen
Journal:  BMC Syst Biol       Date:  2013-12-09

8.  Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.

Authors:  Mariangela Librizzi; John Spencer; Claudio Luparello
Journal:  Int J Mol Sci       Date:  2016-07-30       Impact factor: 5.923

Review 9.  The fate of chemoresistance in triple negative breast cancer (TNBC).

Authors:  Elma A O'Reilly; Luke Gubbins; Shiva Sharma; Riona Tully; Matthew Ho Zhing Guang; Karolina Weiner-Gorzel; John McCaffrey; Michele Harrison; Fiona Furlong; Malcolm Kell; Amanda McCann
Journal:  BBA Clin       Date:  2015-03-12

10.  Chemoresistance to concanamycin A1 in human oral squamous cell carcinoma is attenuated by an HDAC inhibitor partly via suppression of Bcl-2 expression.

Authors:  Tamotsu Kiyoshima; Hisato Yoshida; Hiroko Wada; Kengo Nagata; Hiroaki Fujiwara; Makiko Kihara; Kana Hasegawa; Hirotaka Someya; Hidetaka Sakai
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.